Changing demographics of pulmonary arterial hypertension in congenital heart disease

European Respiratory Review

Volumn 19, Issue 118, 2010, Pages 308-313

  Mulder, B J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Congenital heart disease; Pulmonary arterial hypertension

Indexed keywords

BOSENTAN;

AGE DISTRIBUTION; ARTICLE; CLINICAL FEATURE; CONGENITAL HEART DISEASE; DEMOGRAPHY; DISEASE ASSOCIATION; DOWN SYNDROME; EISENMENGER COMPLEX; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT RIGHT SHUNT; HEART RIGHT LEFT SHUNT; HIGH RISK PATIENT; HUMAN; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG VASCULAR RESISTANCE; MORTALITY; NETHERLANDS; PATHOGENESIS; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC PULMONARY SHUNT; VALVULAR HEART DISEASE;

ADULT; AGE FACTORS; CHILD; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; PREVALENCE; SURVIVAL RATE;

EID: 78650383190     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00007910     Document Type: Article

References (32)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
2. Hoeper MM. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30: 369-375.
3. McLaughlin VV, Preaberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: Suppl. 1, 78S-92S.
4. Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemio-logic perspective from a Dutch registry. Int J Cardiol 2007; 120: 198-204.
5. Vonk MC, Broers B, Heijdra YF, et al. Systemic sclerosis and its pulmonary complications in the Netherlands: an epidemiological study. Ann Rheum Dis 2009; 68: 961-965.
6. Hopkins WE, Ochoa LL, Richardson GW, et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15: 100-105.
7. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007; 115: 1039-1050.
8. Levi DS, Scott V, Aboulhosn J. Pulmonary arterial hyperension in congenital heart disease. In: Humbert M, Lynch III JP, eds. Pulmonary Hypertension. London, Informa Healthcare UK, 2009; pp. 176-195.
9. Galiè N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger syndrome. Drugs 2008; 68: 1049-1066.
10. Vogel M, Berger F, Kramer A, et al. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart 1999; 82: 30-33.
11. Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Circulation 1993; 87: Suppl. 1, I-38-I-51.
12. Vongpatanasin W, Brickner ME, Hillis LD, et al. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128: 745-755.
13. Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006; 27: 1737-1742.
14. Barst RJ, Foreman AJ, Ivy DD, et al. REVEAL Registry: one year outcome of patients with congenital heart disease-associated pulmonary arterial hypertension (CHD-APAH). Am J Respir Crit Care Med 2009; 179: A2656.
15. Dimopoulos K, Inuzuka SG, Giannakoulas G, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary hypertension. Circulation 2010; 121: 20-25.
16. Duffels MG, van der Plas MN, Surie S, et al. Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism. Neth Heart J 2009; 17: 334-338.
17. Duffels MG, Vis JC, van Loon RL, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome. Am J Cardiol 2009; 103: 1309-1315.
18. Duffels MG, Vis JC, van Loon RL, et al. Down patients with Eisenmenger syndrome: is bosentan an option? Int J Cardiol 2009; 134: 378-383.
19. Van Loon RL, Hoendemis ES, Duffels MG. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 2007; 154: 776-782.
20. Perloff JK. Pediatric congenital cardiac becomes a postoperative adult: the changing population of congenital heart disease. Circulation 1973; 47: 606-619.
21. Perloff JK. Congenital heart disease in adults: a new cardiovascular subspecialty. Circulation 1991; 84: 1881-1890.
22. Marelli AJ, Mackie AS, Ionescu-Ittu R, et al. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007; 115: 163-172.
23. Dearani JA, Connolly HM, Martinez R, et al. Caring for adults with congenital cardiac disease: successes and challenges for 2007 and beyond. Cardiol Young 2007; 17: Suppl. 2, 87-96.
24. van der Velde ET, Vriend JW, Mannens MM, et al. CONCOR, an initiative towards a national registry and DNA-bank of patients with congenital heart disease in the Netherlands: rationale, design, and first results. Eur J Epidemiol 2005; 20: 549-557.
25. Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005; 26: 2325-2333.
26. Gatzoulis MA, Alonso-Gonzalez R, Beghetti M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 2009; 18: 154-161.
27. Engelfriet PM, Duffels MG, Möller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007; 93: 682-687.
28. Weijerman ME, van Furth AM, van der Mooren MD, et al. Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome. Eur J Pediatr 2010; 169: 1195-1199.
29. Malec E, Mroczek T, Pajak J, et al. Results of surgical treatment of congenital heart defects in children with Down's syndrome. Pediatr Cardiol 1999; 20: 351-354.
30. Suzuki K, Yamaki S, Mimori S, et al. Pulmonary vascular disease in Down's syndrome with complete atrioventricular septal defect. Am J Cardiol 2000; 86: 434-437.
31. Van de Bruaene A, Delcroix M, Pasquet A, et al. The Belgian Eisenmenger syndrome registry: implications for treatment strategies? Acta Cardiol 2009; 64: 447-453.
32. Vis JC, Thoonsen H, Duffels MG, et al. Six-minute walk test in patients with Down syndrome: validity and reproducibility. Arch Phys Med Rehabil 2009; 90: 1423-1427.